CN102283828B - 四羟基苯并吡喃酮类化合物的用途 - Google Patents
四羟基苯并吡喃酮类化合物的用途 Download PDFInfo
- Publication number
- CN102283828B CN102283828B CN 201010201015 CN201010201015A CN102283828B CN 102283828 B CN102283828 B CN 102283828B CN 201010201015 CN201010201015 CN 201010201015 CN 201010201015 A CN201010201015 A CN 201010201015A CN 102283828 B CN102283828 B CN 102283828B
- Authority
- CN
- China
- Prior art keywords
- compound
- carcinoma
- alpha36
- formula
- breast cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 tetrahydroxybenzopyrone compound Chemical class 0.000 title abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 68
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 36
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 33
- 201000010099 disease Diseases 0.000 claims abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 15
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 10
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 10
- 206010039966 Senile dementia Diseases 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 10
- 208000019622 heart disease Diseases 0.000 claims abstract description 9
- 208000006673 asthma Diseases 0.000 claims abstract description 8
- 108010038795 estrogen receptors Proteins 0.000 claims abstract description 7
- 102000015694 estrogen receptors Human genes 0.000 claims abstract 2
- 102100038595 Estrogen receptor Human genes 0.000 claims description 89
- 101710196141 Estrogen receptor Proteins 0.000 claims description 78
- 201000008275 breast carcinoma Diseases 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000001514 prostate carcinoma Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 230000001055 chewing effect Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 33
- 206010028980 Neoplasm Diseases 0.000 abstract description 19
- 230000014509 gene expression Effects 0.000 abstract description 14
- 238000002474 experimental method Methods 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 3
- 208000020446 Cardiac disease Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000003399 chemotactic effect Effects 0.000 abstract 1
- 210000002540 macrophage Anatomy 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 description 15
- 239000001257 hydrogen Substances 0.000 description 15
- YHQXBTXEYZIYOV-UHFFFAOYSA-N 3-methylbut-1-ene Chemical group CC(C)C=C YHQXBTXEYZIYOV-UHFFFAOYSA-N 0.000 description 12
- 230000009182 swimming Effects 0.000 description 11
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 8
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 238000001228 spectrum Methods 0.000 description 8
- 241000705930 Broussonetia papyrifera Species 0.000 description 7
- 150000002431 hydrogen Chemical class 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- 229940011871 estrogen Drugs 0.000 description 6
- 239000000262 estrogen Substances 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- BKOOMYPCSUNDGP-UHFFFAOYSA-N trimethyl-ethylene Natural products CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000011580 nude mouse model Methods 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 229960001603 tamoxifen Drugs 0.000 description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 229960001866 silicon dioxide Drugs 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010041356 Estrogen Receptor beta Proteins 0.000 description 3
- 102100029951 Estrogen receptor beta Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229940046836 anti-estrogen Drugs 0.000 description 3
- 230000001833 anti-estrogenic effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000000328 estrogen antagonist Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 201000010983 breast ductal carcinoma Diseases 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000004994 reproductive system Anatomy 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010007005 Estrogen Receptor alpha Proteins 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000069 breast epithelial cell Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000004964 innate lymphoid cell Anatomy 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010201015 CN102283828B (zh) | 2010-06-17 | 2010-06-17 | 四羟基苯并吡喃酮类化合物的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010201015 CN102283828B (zh) | 2010-06-17 | 2010-06-17 | 四羟基苯并吡喃酮类化合物的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102283828A CN102283828A (zh) | 2011-12-21 |
CN102283828B true CN102283828B (zh) | 2013-05-15 |
Family
ID=45330767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201010201015 Active CN102283828B (zh) | 2010-06-17 | 2010-06-17 | 四羟基苯并吡喃酮类化合物的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102283828B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101539978B1 (ko) * | 2012-09-27 | 2015-07-30 | 사단법인 분자설계연구소 | 크로멘-4-온 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 골형성 촉진용 약학적 조성물 |
CN102977065B (zh) * | 2012-12-06 | 2014-10-29 | 云南烟草科学研究院 | 一种黄酮类化合物及其制备方法与应用 |
CN106588947B (zh) * | 2016-12-07 | 2018-08-10 | 江西中医药大学 | 波罗蜜中的异戊烯基黄酮类化合物及其抗骨质疏松新用途 |
IT201700075637A1 (it) * | 2017-07-05 | 2019-01-05 | Vera Salus Ricerca S R L | Composto per la cura dei tumori maligni |
CN113057955B (zh) * | 2021-03-09 | 2023-03-24 | 江南大学 | 一种用于抑制硬脂酰辅酶a去饱和酶1的药物 |
CN114392255A (zh) * | 2021-11-10 | 2022-04-26 | 甘肃中医药大学 | 乌拉尔醇的新应用 |
-
2010
- 2010-06-17 CN CN 201010201015 patent/CN102283828B/zh active Active
Non-Patent Citations (2)
Title |
---|
于令军.《前言、植物雌激素样活性研究》.《异戊烯基黄酮类化合物的合成方法及其雌激素样活性研究》.2005,第4页,第31页. * |
沈丽霞等.《实验二 流式细胞仪检测槲皮素、补骨脂素对人乳腺癌细胞周期的影响》.《槲皮素和补骨脂素对人乳腺癌细胞株雌激素样作用的实验研究》.2008,第62页. * |
Also Published As
Publication number | Publication date |
---|---|
CN102283828A (zh) | 2011-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102283828B (zh) | 四羟基苯并吡喃酮类化合物的用途 | |
CN105517989B (zh) | 大麻素类化合物的混合物及其制备和用途 | |
Wang et al. | Licochalcone A from licorice root, an inhibitor of human hepatoma cell growth via induction of cell apoptosis and cell cycle arrest | |
Han et al. | Ginsenoside 20 (S)-Rh2 exerts anti-cancer activity through targeting IL-6-induced JAK2/STAT3 pathway in human colorectal cancer cells | |
Chan et al. | Polyphyllin D, a steroidal saponin from Paris polyphylla, inhibits endothelial cell functions in vitro and angiogenesis in zebrafish embryos in vivo | |
CN103204838B (zh) | 多羟基苯并吡喃酮类化合物的合成及其抗肿瘤作用 | |
CN103193860B (zh) | 丹参酮类化合物、制备方法及其用途 | |
CN101396421A (zh) | 具有雌激素样作用的中药组合物及其应用 | |
Pan et al. | Daphnane diterpenoids from Daphne genkwa inhibit PI3K/Akt/mTOR signaling and induce cell cycle arrest and apoptosis in human colon cancer cells | |
CN105194550A (zh) | 一种中药复方组合物及其在抗前列腺癌中的应用 | |
Lee et al. | New estrogenic compounds isolated from Broussonetia kazinoki | |
CN102285948B (zh) | 四羟基苯并吡喃酮类化合物及其用途 | |
CN102283823B (zh) | 四羟基丙烯酮类化合物的用途 | |
CN102038673B (zh) | 羟基苯并吡喃酮类化合物在制备治疗白血病药物中的应用 | |
CN113509459A (zh) | 黄烷类化合物在制备抗肿瘤的药物中的用途 | |
CN110218198A (zh) | 一种萘醌并三氮唑核心骨架衍生物化合物及其制备方法和应用 | |
CN101574386B (zh) | 雷公藤活性成分调控热休克蛋白和视黄醇X受体α的应用 | |
CN105837592B (zh) | 间苯三酚骈松香烷二萜类化合物及其制备方法和药物用途 | |
CN101249087A (zh) | 异补骨脂黄酮在制备抗肿瘤,骨质疏松,老年痴呆药中的应用 | |
CN107674054A (zh) | 一类新骨架杂萜化合物,其制备方法、药物组合物和抗肿瘤应用 | |
CN101288666A (zh) | 异补骨脂查耳酮在制备抗肿瘤,骨质疏松,老年痴呆药中的应用 | |
CN106562956A (zh) | 一种天然产物Eupalinolide J的新用途 | |
CN101199509B (zh) | 2",2"-二甲基-2"h,4h-3,6"-二苯并吡喃-4-酮在制备抗肿瘤药物中的用途 | |
CN101185643B (zh) | (e)-1-(2,4-二羟基-5-(3-甲基-丁基-2-烯基)苯基)-3-(4-羟基苯基)丙烯-2-酮-1在药物中的应用 | |
CN101249088A (zh) | 补骨脂二氢黄酮甲醚在制备抗肿瘤,骨质疏松,老年痴呆药中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Ding Hongxia Inventor after: Li Jing Inventor after: Meng Kun Inventor before: Li Jing Inventor before: Meng Kun |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LI JING MENG KUN TO: DING HONGXIA LI JING MENG KUN |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 102206 B101 room, innovation building, Zhongguancun Life Science Park, No. 29, life science Road, Beijing, Changping District Patentee after: BEIJING SHENOGEN PHARMA Group Ltd. Address before: 100085 A205 room, Zhongguancun Medicine Park, No. 5, Pioneer Road, Beijing, Haidian District Patentee before: BEIJING SHENOGEN PHARMA Group Ltd. |
|
DD01 | Delivery of document by public notice |
Addressee: BEIJING SHENOGEN PHARMA Group Ltd. Document name: Notification of Passing Examination on Formalities |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Application of tetrahydroxybenzopyrone compound Effective date of registration: 20150410 Granted publication date: 20130515 Pledgee: Beijing Intellectual Property Management Co.,Ltd. Pledgor: BEIJING SHENOGEN PHARMA Group Ltd. Registration number: 2015990000275 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20160511 Granted publication date: 20130515 Pledgee: Beijing Intellectual Property Management Co.,Ltd. Pledgor: BEIJING SHENOGEN PHARMA Group Ltd. Registration number: 2015990000275 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
CP01 | Change in the name or title of a patent holder |
Address after: 102206 B101 room, innovation building, Zhongguancun Life Science Park, No. 29, life science Road, Beijing, Changping District Patentee after: Beijing shengnuoji Pharmaceutical Technology Co.,Ltd. Address before: 102206 B101 room, innovation building, Zhongguancun Life Science Park, No. 29, life science Road, Beijing, Changping District Patentee before: BEIJING SHENOGEN PHARMA Group Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Use of tetrahydroxybenzopyranone compounds Effective date of registration: 20220421 Granted publication date: 20130515 Pledgee: China Minsheng Bank Co.,Ltd. Beijing Branch Pledgor: Beijing shengnuoji Pharmaceutical Technology Co.,Ltd. Registration number: Y2022990000225 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230407 Granted publication date: 20130515 Pledgee: China Minsheng Bank Co.,Ltd. Beijing Branch Pledgor: Beijing shengnuoji Pharmaceutical Technology Co.,Ltd.|BEIJING SHENOGEN BIOMEDICAL Co.,Ltd. Registration number: Y2022990000225 |